

REVISTA DECANA DE LA ESPECIALIDAD

TOKO-GINECOLOGÍA

PRÁCTICA

March - April 2020

Year MMXX

769

Prevention and treatment of low-grade cervical lesions caused by HPV: evidence for a vaginal gel based on *Coriolus versicolor*

Dexeus Damián, Agüera Javier, Calderón María Angeles, Centeno Crisitina, Coronado Pluvio, De la Fuente Jesús, De Santiago Javier, Donaire Maria Concepción, Fiol Gabriel, Garcia Carmen, González Silvia, Gurrea Marta, Hernández Juan José, Lago Víctor, Lobo Ignacio, López Andrés Carlos, López José Antonio, Losa Fernando, Lubrano Amina, Mancebo Gemma, Palacios Santiago, Quesada Alfonso, Riera Margarita, Rodríguez Inmaculada, Serrano Luis, Solé-Sedeno Josep Maria, Valenzuela Orlando, Vanrell Cristina, Mallafré Anna, Cortés Javier

Introduction made by Dr. Charles Redman (UK)
Past President of the European Federation of
Colposcopy (EFC)



Dr. Charles Redman

*Past President of the European Federation of
Colposcopy (EFC)*

Department of Obstetrics and Gynaecology

University Hospital of North Staffordshire

Stoke-on-Trent, UK ST4 6QG

Tel: + 44 (0) 1782 672794

Email: cweraf@icloud.com

INTRODUCTION

Scientific and technological advances have resulted in the detection of more high-risk human papillomavirus (HPV) infections and women with associated cervical intraepithelial neoplasia (CIN) than ever before though, hitherto, the traditional options remain as either masterly inactivity or surgery.

We know that nearly all sexually active adults will acquire HPV at some point in their lifetimes¹. The vast majority of these infections are transitory and 90% are spontaneously cleared or become inactive within 12 to 24 months of exposure to the virus^{2,3,4}. Nonetheless, in some women the infections persist and in these women there is a risk of developing precancerous.

It is recognised that the likelihood of persistence is related to the type of HPV. More than 150 subtypes of HPV have been identified which can be classified into 2 groups depending on their oncogenic capacity, namely, viruses with a low risk of progression to cancerous lesions (LR-HPV) and viruses with a high risk of progression to cervical cancer (HR-HPV). The main serotypes in this group are 16, 18, and 31, which are more directly associated with persistence of the virus. Persistent infection with an oncogenic or HR-HPV type is the main risk factor for detecting a CIN that may range from CIN1 to CIN3 and, ultimately, cancer^{3,5,6}.

The potential health burden caused by HPV is immense. In Europe, approximately 60,000 women are diagnosed with cervical cancer every year of whom about 26,000 will die from the disease⁷ yet this represents but a tiny proportion of those who have been infected with HPV. In only a fraction of those infected will the virus persist and go on to develop CIN. Even then, a significant proportion of cases will resolve, particularly in young women. Up to 70% of women aged 30 or less with CIN2 will regress spontaneously⁸ and colposcopists are increasingly reluctant to subject young women to potentially harmful cervical treatment with the recognised associated obstetric morbidity⁹.

These considerations pose a real problem for cervical screening programmes, particularly if primary HPV testing is used. Many well and asymptomatic women will screen positive and experience with the associated anxiety^{10,11}, yet still be at a relatively low risk of developing cervical cancer or requiring treatment of CIN. In some cases, particularly if further tests are normal or low grade, conservative management will be advised even if referred for colposcopy. Given that such an approach may last for months this can be challenging both for the patient and clinicians. It follows that in these circumstances there is a demand for a safe, non-surgical treatment that might enhance viral clearance.

HPV infection alone is not the only determinant of outcome. Other factors, such as host immunity, histological structure of the ectocervix and transformation zone, plus the state of the vaginal microbiota all play a role, which is still poorly defined, but which may be essential for progression or regression of the infection¹². Influencing some of these factors may provide an opportunity for improved clearance of the virus and reduction in risk.

REFERENCES

1. Chesson HW, Dunne EF, Hariri S and Marovitz LE. The Estimated Lifetime Probability of Acquiring Human Papillomavirus in the United States. *Sex Transm Dis* 2014;41:660-664.
2. Reid R, Stanhope CR, Herschman BR, Booth E, Pibbs ED, and Smith JR. Genital warts and cervical cancer. I. Evidence of an association between subclinical papillomavirus infection and cervical malignancy. *Cancer* 1982;50:377–387.
3. Stanley M. Pathology and epidemiology of HPV infection in females. *Gynecol Oncol* 2010;117:S5–S10.
4. Skinner SR, Wheeler CM, Romanowski B et al. Progression of HPV infection to detectable cervical lesions or clearance in adult women: analysis of the control arm of the VIVIANE study. *Int J Cancer* 2016;138:2428–2438.
5. Asiaf A, Ahmad ST, Mohammad SO, Zargar MA. Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. *Eur J Cancer Prev* 2014;23:206–224.
6. Mirabello L, Clarke MA, Nelson CW et al. The intersection of HPV epidemiology, genomics and mechanistic studies of HPV-mediated carcinogenesis. *Viruses* 2018;10(2):80.
7. Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Europe. Summary Report 17 June 2019. [01 June 2020].
8. Taino K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cardenas J, Hernandez A et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. *BMJ* 2018;360:l499.
9. Arbyn M, Kyrgiou M, Simoons C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: Metaanalysis. *BMJ* 2008;337:798– 803.
10. Hellsten C, Sjöström K, Lindqvist PG. A longitudinal 2-year follow-up of quality of life in women referred for colposcopy after an abnormal cervical smear. *Eur J Obstet Gynecol Reprod Biol* 2009;147:221-225.
11. Thangarajah F, Einzmann T, Bergauer TF, Patzke J, Schmidt-Petruschkat S, et al. Cervical screening program and the psychological impact of an abnormal Pap smear: a self-assessment questionnaire study of 590 patients. *Arch Gynecol Obstet* 2016;293:391-398.
12. Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub AY. Ecological dynamics of the vaginal microbiome in relation to health and disease. *Am J Obstet Gynecol*. 2019;220:324-35.

Original

Prevention and treatment of low-grade cervical lesions caused by HPV: evidence for a vaginal gel based on *Coriolus versicolor*

Dexeus D¹, Agüera J², Calderón MA³, Centeno C⁴, Coronado P⁵, de la Fuente J⁶, De Santiago J⁷, Donaire MC⁸, Fiol G⁹, García C¹⁰, González S¹¹, Gurrea M¹², Hernández JJ¹³, Lago V¹⁴, Lobo I¹⁵, López AC¹⁶, López JA¹⁷, Losa F¹⁸, Lubrano A¹⁹, Mancebo G²⁰, Palacios S²¹, Quesada A²², Riera M²³, Rodríguez I²⁴, Serrano L²⁵, Solé-Sedeno JM²⁶, Valenzuela O²⁷, Vanrell C²⁸, Mallafré A²⁹, Cortés J³⁰

¹ Womens Health Institute, Barcelona. damiandexeus@gmail.com

² Hospital de Manacor, Baleares. jaguera@hmanacor.org

³ Hospital Virgen de las Nieves (FIBAO), Granada. mangelos00@gmail.com

⁴ Clínica Diatros, Barcelona. criscen@telefonica.net

⁵ Hospital Clínico San Carlos, Madrid. pcoronadom@gmail.com

⁶ Hospital Infanta Leonor, Madrid. delavalero@gmail.com

⁷ MD Anderson, Madrid. jsantiagoo@hotmail.es

⁸ Hospital General Universitario, Alicante. conchi-don@gmail.com

⁹ Hospital Universitario Torrecárdenas, Almería. gabriel@sego.es

¹⁰ Centro ginecológico, HM San Francisco. León. carmengarciaferreiro@yahoo.es

¹¹ HM Gabinete Velázquez, Madrid. silviapgonzalez@yahoo.es

¹² Hospital Universitari i Politècnic La Fe, Valencia. martagurrea@gmail.com

¹³ Hospital Universitario Infanta Leonor, Madrid. jhemandez@salud.madrid.org

¹⁴ Hospital Universitari i Politècnic LaFe, Valencia. victor.lago.leal@hotmail.com

¹⁵ Hospital de Basurto, Bilbao. ilobol@hotmail.com

¹⁶ Hospital Quirónsalud, Málaga. alopezdiaz@gmail.com

¹⁷ Hospital General Universitario, Alicante. lopez_josfer@gva.es

¹⁸ Clínica Sagrada Família, Barcelona. losa.fernando@gmail.com

¹⁹ Complejo Hospitalario Universitario Insular Materno Infantil. Las Palmas de Gran Canaria. alubranorosales@gmail.com

²⁰ Hospital del Mar, Barcelona. gmancebo@psmar.cat

²¹ Instituto Palacios de Salud y Medicina de la Mujer, Madrid. spalacios@institutopalacios.com

²² Hospital Universitario Ntra. Sra. de Candelaria. Sta Cruz de Tenerife. aquelop@gmail.com

²³ ASSIR Hospitalet de Llobregat mrierablasco@hotmail.com

²⁴ Hospital Universitario Virgen Macarena, Sevilla. Rodriguezjimenezinmaculada@gmail.com

²⁵ HM Gabinete Velázquez, Madrid. luisseranocogollor@gmail.com

²⁶ Hospital del Mar, Barcelona. jsol@psmar.cat

²⁷ Hospital Álvaro Cunqueiro, Vigo. orvabe@hotmail.com

²⁸ Hospital de la Santa Creu i Sant Pau, Barcelona. cvanrell@santpau.cat

²⁹ Procure Health Iberia, Castelldefels. mallafré.a@procurehealth.com

³⁰ Práctica Privada, Palma de Mallorca. cortes@oceas.es

CORRESPONDENCE:

Damián Dexeus

Womens Health Institute

Barcelona.

damiandexeus@gmail.com

INTRODUCTION

Human papillomavirus (HPV) and cervical lesions currently have a major impact in Spain, where, every year, around 370,000 low-grade lesions (low-grade squamous intraepithelial lesion [LSIL] or atypical cells of uncertain significance [ASCUS]) and 2,500 cases of cervical cancer are diagnosed. However, the most striking finding is that HPV testing is positive in approximately 2 million women¹. The magnitude of the problem of HPV

for society as a whole is seen clearly in Figure 1, where the pyramid shows that cervical cancer is a rare yet preventable complication of a very common infection.




Fig.1. Pyramid illustrating the incidence of HPV in Spain (adapted from the vaccination guide of AEPPC 2014)²

HPV infection is the most common sexually transmitted infection in the world, and cervical cancer is the second most common type of cancer in women². More than 150 subtypes of HPV have been identified; of these, 40-50 can produce genital lesions. According to Bouvard, these viruses can be classified into 2 groups depending on their oncogenic capacity, namely, viruses with a low risk of progression to cancerous lesions (LR-HPV) and viruses with a high risk of progression to cervical cancer (HR-HPV). The main serotypes in this group are 16, 18, and 31, which are more directly associated with persistence and with cervical cancer³.

HPV is very prevalent and has a high clearance rate in women aged <30 years. However, the rate of clearance of HR-HPV at 6 and 18 months stands at 29% and 41%, respectively; in the case of HPV-16 in particular, the clearance rate is only 9% at 6 months and 19% at 18 months, which is much lower than rates for the other serotypes and is highly consistent with the potential malignant transformation of this serotype⁴.

Today, we know that HPV infection is a necessary but not the only condition for developing the disease and that identification of the HPV serotype responsible for the disease is not the only determinant of outcome. Other factors, such as host immunity, histological structure of the exocervix and transformation zone, and the state of the vaginal microbiota also play a role, which is still poorly

defined, but which may be essential for progression or regression of the infection⁵.

VAGINAL GEL BASED ON CORIOLUS VERSICOLOR

Given this initial situation, we began to evaluate a vaginal gel, Papilocare® (Procure Health Iberia), which is composed of ingredients that act synergistically to enable a positive effect on modifiable factors. The gel aims to enhance epithelialization of the cervix in order to minimize the window of opportunity for viral entry, to improve the microbiota and thus create a less favorable state for persistence of the virus, and to generate favorable conditions for natural immunity that would enable viral clearance and healing of lesions.

The clinical development of this product comprises several trials and studies performed during recent years, including an initial study in HPV-infected patients that revealed a significant improvement in cervical epithelialization and vaginal health⁶. The first study of HPV-positive women was the EPICERVIX pilot study⁷, which included a sample of 21 patients with no lesions in cytology, and a normal colposcopy result. Patients underwent an exploratory investigation to determine the effect of applying vaginal gel daily for 21 days on cervical epithelialization and on vaginal microbiota.

The degree of ectopia was evaluated using colposcopy and then assessed by an investigator using a Likert-type scale ranging from 1 (severe ectopia and bleeding) to 5 (no ectopia). The composition of the microbiota was determined using pyrosequencing of the 16S rRNA gene (Illumina MiSeq sequencing). Changes in biodiversity were evaluated using the Shannon index (<2, low biodiversity; 2-3, normal biodiversity; and >3 high biodiversity) and based on the proportion of microorganisms in the vagina.

Epithelialization of the cervix improved in 52.6% of patients and remained stable in 47.7%. No patients worsened. At the end of the study, 63.2% of patients had normal cervical epithelialization compared with 38.1% at baseline. In addition, significant changes in vaginal microbiota were observed at the end of the study. Biodiversity decreased significantly as the concentration of autochthonous species increased and that of pathogenic species decreased (Figure 2).




Fig.2. Results for vaginal microbiota in the Epicervix study⁷

The EPICERVIX study revealed a significant improvement in epithelialization of the cervix in HPV-infected persons in the absence of lesions and confirmed that it was possible to modify the composition of the microbiota, thus reducing the considerable biodiversity associated with vaginal dysbiosis and increasing the concentration of lactobacilli.

A more wide-ranging study, the PALOMA trial, was started to advance the development of the product and to confirm these findings.

THE PALOMA CLINICAL TRIAL

Methods

The PALOMA clinical trial⁸⁻¹⁰ is a multicenter, open-label, parallel-group randomized clinical trial with a control group that was designed to explore the efficacy of Papilocare® gel for treatment of lesions of the cervical mucosa caused by HPV.

We included HPV-positive patients aged between 30 and 65 years with a cytology indicating ASCUS or LSIL and a compatible colposcopy image.

The exclusion criteria were previous HPV vaccination and clinically relevant abnormalities such as pregnancy, immunosuppression, and abnormal genital bleeding.

The patients included were randomized to 1 of 3 arms: 2 arms with the vaginal treatment in different regimens and 1 control arm (routine clinical practice, ie, wait and see approach). Fig.3.

The primary endpoint was the percentage of patients with repair of cervical lesions according to cytology and compatible colposcopy image 6 months after starting treatment.

The secondary endpoints analyzed included the percentage of patients with clearance of HPV according to a

PCR genotyping assay (Clart HPV4®) and stress perceived by the patient using a questionnaire (14-item Perceived Stress Scale [PSS-14]).

Other variables evaluated included tolerability, satisfaction, and adherence to treatment with Papilocare® gel.

Detection and identification of HPV and evaluation of cytology

findings was centralized under triple-blind conditions at the Instituto de Estudios Celulares y Moleculares (ICM), Lugo, Spain.

The main analysis was performed between 2 groups: the treatment group (both arms) and the control group. The intention-to-treat population was analyzed: patients who received at least 1 application of the investigational product and had at least baseline values and a posttreatment value for the primary endpoint.

A subanalysis was performed to assess the repair of lesions and viral clearance in patients with HR-HPV by any of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.

Results

We recruited a total of 91 patients, of whom 84 attended the final visit after 6 months of treatment. The mean age of the patients was 41.3 years in the treatment group and 39.2 years in the control group. The frequency of HR-HPV was 75% in both groups and the baseline characteristics were similar.




Fig.3. Design of the PALOMA trial⁸

Of the 84 patients who attended the final visit, the lesions had healed (normalization of ASCUS/LSIL cytology findings together with a concordant colposcopy image) in 85% of patients in the treatment group compared with 65% in the control group. In the HR-HPV population (n=66), the lesions had healed in 88% of the Papilocare® group and in 56% of the control group. The differences were significant in both cases. Fig.4.




Fig.4. Repair of lesions affecting the cervix at 6 months in the PALOMA trial⁹

As for clearance of HR-HPV, it was noteworthy that the group treated with Papilocare® cleared 63% of the virus at 6 months compared with 40% in the control group, that is, a 57% higher rate of clearance. Fig.5.

Stress during the 6-month period was also very important. The sensation of stress tended to decrease more in terms of the mean PSS-14 score in both groups and in terms of the percentage of patients whose score on the questionnaire improved: 58% vs 39% of patients improved with respect to the sensation of stress in the Papilocare® and control groups, respectively.

Similarly, the study showed the tolerability of the product to be favorable and its safety to be adequate: no severe or unexpected adverse effects associated with the product were recorded. The most frequent adverse effect was itching or irritation. Patients were generally satisfied with the product (87%), and adherence was very good (93.4% at 6 months).




Fig.5. Clearance of high-risk HPV at 6 months in the PALOMA trial⁹

REAL-WORLD DATA

In line with the product development plan, the PAPIOBS study was designed to assess Papilocare® in daily clinical practice¹¹.

The study, which is currently under way, is a noncomparative observational multicenter study whose main objective is to evaluate the effectiveness of Papilocare® for treatment of low-grade cervical lesions caused by HPV (normalization of the cytological ASCUS or LSIL with compatible colposcopy findings) in women aged >25 years who tested positive for HPV. Similarly, total or partial clearance of HPV was set as a secondary objective. Patients are treated with the standard schedule of Papilocare® (1 cannula per day for the first month and 1 cannula on alternate days for 5 months). The patient is evaluated at 6 months and, if the expected results are not achieved, a second cycle of treatment can be offered with a further evaluation after 6 months.

We currently have interim results for 97 patients. The mean age of the population analyzed was 38.6 years; HR-HPV was detected in 92.1% of patients. After 6 months of treatment, 66% had normal cytology findings and a concordant negative colposcopy result, with normalization of findings in 91% of patients at 12 months. This last finding is particularly relevant, since continuing treatment for 6 months made it possible

to achieve normal results for a larger number of cervical lesions.

In addition, HR-HPV cleared in 63% of patients at 6 months and in 82% at 12 months.

In this interim analysis, Papilocare® proved to have a notable effect for treatment of low-grade HPV-dependent cervical lesions and on clearance of HPV under real-world conditions. The objective of therapy was reached after 6 months' treatment in most patients, and at 12 months, it was achieved in 91%.

The effectiveness of Papilocare® in clearance of HR-HPV has also been evaluated in independent observational clinical studies, some of which were prospective, in 3 public hospitals in Spain¹²⁻¹⁴ and in a private center in Italy¹⁵. Fig 6. As seen in Figure 7, the results for clearance with Papilocare® are especially coherent and reproducible, both under clinical trial conditions and under real-world conditions: clearance was recorded in 50% to 70% of cases of HR-HPV at 6 months in more than 700 patients^{16,17}.

CONCLUSIONS

In conclusion, Papilocare® is the first and only treatment in Europe that is indicated for the prevention and treatment of low-grade HPV-dependent lesions.

The gel is a unique combination of natural ingredients selected to act on 3 modifiable factors in viral clearance.

The 6-month rates for healing of lesions and viral clearance in patients with HR-HPV, together with the reduced the sensation of stress and high degree of satisfaction and tolerability of treatment in the abovementioned studies, favor offering vaginal gel to HPV-infected patients with low-risk cervical lesions (ASCUS or LSIL) as opposed to the wait-and-see approach used in routine clinical practice.



Fig.6. Design and characteristics of independent observational studies carried out with Papilocare®¹⁷




Fig.7. Results for clearance of high-risk HPV in the PALOMA trial and observational studies with Papilocare®¹⁷

With the aim obtaining more in-depth knowledge and determining the extent of the effects of Papilocare® vaginal gel, a major international clinical development plan is under way, with more than 1000 patients in various ongoing studies.

REFERENCES

1. Castellsagué X. Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study. *J Med Virol*. 2012;84:947-56.
2. Campins M, Alemany L, Bayas JM, Borruel N, Campins M, Castellsagué X et al. AEPCC-Guía: Vacunación selectiva frente al virus del papiloma humano en poblaciones de riesgo elevado. AEPCC. 2014 p.1-46.
3. Puig Tintoré LM. Neoplasia intraepitelial de cérvix (CIN). Diagnóstico, tratamiento y seguimiento. En: Cabero Roura, L. editor. Tratado de ginecología, obstetricia y medicina de la reproducción. SEGO. Madrid. 2003 p.1544-58.
4. Bulkman NW, Berkhof J, Bulk S, Bleeker MC, van Kemenade FJ, Rozendaal L, Snijders PJ, Meijer CJ. *Br J Cancer*. 2007;96(9):1419-24.
5. Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub AY. Ecological dynamics of the vaginal microbiome in relation to health and disease. *Am J Obstet Gynecol*. 2019 Apr;220(4):324-35.
6. Palacios S, Losa F, Dexeus D, Cortés. Beneficial effects of a *Coriolus versicolor*-based vaginal gel on cervical epithelization, vaginal microbiota and vaginal health: a pilot study in asymptomatic women. *BMC Women's Health*. 2017;17:21.
7. Serrano L, González S, Gálvez J, Rodríguez Nogales A, Vezza T, Garrido Mesa J, Algieri F, Rodríguez Cabezas ME. Effect of a *Coriolus Versicolor*-Based Vaginal Gel in HPV+ Women With No Colposcopy Cervical Lesions [Abstract]. A Pilot Study. *J Low Genit Tract Dis*. 2018 Apr; 22(2S): S22.
8. Palacios S, Dexeus D, Serrano L, González S, López AC, Centeno C, Coronado P, de la Fuente J, López Fernández J, Vanrell C, Cortés J. Design of a phase 2 randomised, controlled, parallel-group, open-label, multicenter trial to explore the effectiveness of a *Coriolus versicolor*-based gel on restoration of cervicovaginal mucosal lesions caused by human papilloma virus (The Paloma Clinical Trial.) *ClinicalTrials.gov* Identifier NCT04002154.
9. Serrano L, López AC, González S, Palacios S, Dexeus D, Centeno C, Coronado P, de la Fuente J, López Fernández JA, Vanrell C, Cortés J. Effect of a *Coriolus versicolor*-based vaginal gel in HPV infected women: normalizing HPV-dependent cervical lesions (ASCUS/LSIL) and high-risk HPV clearance. [Abstract]. *Int J Gynecol Cancer* 2019;29:A206-07.
10. Seydoux G, Cortés J, Serrano L, López AC, González S, Palacios S, Dexeus D, Centeno C, Coronado P, de la Fuente J, López Fernández JA, Vanrell C,. Effect of a multi-ingredient vaginal gel in HPV+ women: cervical reepithelization, stress and tolerability. [Abstract]. *J Low Genit Tract Dis*. 2020 April; 24(1S):S16. doi:10.1097/LGT.0000000000000538
11. Emsellem C, Cortés J, De Santiago J, Cos A, Lago I, Espinosa G, Olalla MA, Fiol G, Lozada C, García C, Agenjo M. Efficacy of a multi-ingredient vaginal gel in repairing HPV-dependent cervical lesions in real-life: interim analysis. [Abstract]. *J Low Genit Tract Dis*. 2020 April; 24(1S):S16-S17. doi:10.1097/LGT.0000000000000538
12. Riera Blasco MR, Rupérez Pérez B, Lázaro Vicario I, Felgueroso A, Fontanet Pérez E, Aguayo Alba A. *Coriolus versicolor* and treatment of high-risk HPV. [Abstract]. *J Low Genit Tract Dis*. 2018 April; 22(2S):S9.
13. Marín Ortiz E, Vázquez Caamaño MP, Porto Quintans M, Valenzuela Besada O, Gil Andrés M, Iñarrea Fernández A. Efficacy of a *Coriolus versicolor*-based vaginal gel in high-risk HPV+ women. Preliminary results. [Abstract]. International Papillomavirus Conference, IPVC 2018. Sydney, Australia. Disponible en: https://ipvc2018.org/PublishingImages/abstract-information/ipvc-2018-submitted-abstracts/IPVC18_-_All_abstracts_for_website.pdf
14. Gajino Suárez C. Use and results of a *Coriolus versicolor*-based vaginal gel in women HPV+ and/or abnormal pap smear attended in a regional Spanish hospital. Preliminary analysis. [Abstract]. International Papillomavirus Conference, IPVC 2018. Sydney, Australia. Disponible en:

- https://ipvc2018.org/PublishingImages/abstract-information/ipvc-2018-submitted-abstracts/IPVC18_-_All_abstracts_for_website.pdf
15. Minniello G. Prevenzione e Trattamento Coadiuvante delle Lesioni della Cervice Uterina indotte da HPV: un'Esperienza di "Real Life". *Momenti di Medicina e Chirurgia*. 2018 Dec;4(1):1-18.
 16. Riera M, Rupérez B, Lázaro I, Felgueroso A, Fontanet E, Tena Y, Combalia J. Effect of a Multi-Ingredient Vaginal Gel on Clearance and/or Cytology Normalization in High-Risk HPV Positive Patients [Abstract]. *J Low Genit Tract Dis*. 2020 April; 24(1S):S16. doi: 10.1097/LGT.0000000000000538
 17. Gaslain Y, Cortés J, Dexeus D, Palacios S, Serrano L, Seydoux G, Gajino C, Marín E, Riera M. Effect of a multi-ingredient vaginal gel in high-risk HPV infected patients: results of different studies [Abstract]. *J Low Genit Tract Dis*. 2020 April; 24(1S):S15-S16. doi: 10.1097/LGT.0000000000000538.



PAPILOCARE®

1st TREATMENT TO PREVENT AND TREAT HPV-DEPENDENT
CERVICAL LESIONS^{1,2}

Phase II, randomised, open-label, parallel-group, controlled clinical trial on the efficacy of
PAPILOCARE® vaginal gel in repairing the cervico-vaginal HPV-dependent lesions^{1,2}

**NEW
PRESENTATION**

**21%
OFF**



21 cannulas of 5 ml
presentation

7 cannulas of 5 ml
presentation

NORMALIZATION OF HPV-DEPENDENT
CERVICAL LESIONS IN

88%

of High-Risk HPV+ patients
at 6 months vs 56% in the
control group

**FINAL
RESULTS
on High-Risk
HPV**

HPV CLEARANCE IN

63%

of High-Risk HPV+ patients
at 6 months vs 40% in the
control group



**p=0.0034

HR-HPV: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68



RECOMMENDED TREATMENT DURATION: 6 MONTHS

Instructions for use:



- Start treatment after period.
- Insert a single-dose cannula into the vagina, preferably before bedtime.
- Stop during the period, if exists.

(Low grade lesions: ASCUS/LSIL)

**x21
CANNULAS**

**COMPLIANCE
CONVENIENCE
PRICE**

Procure
Health
Naturally woman

References:

1. Sánchez L, López R, González S, Palacios F, Durán D, Garmier C, Corrado R, de la Fuente J, López Hernández JA, Vives C, Carballo J and Gómez J. 2021a Effect of a Cervical vaccination against vaginal gel in HPV infection among immunizing HPV dependent cervical lesions (ASCUS/LSIL) and high-risk HPV (HPV) lesions. International Journal of Gynecological Cancer 2021;30(2):266. 2. Sánchez L, Fariña J, Soriano L, López AC, González S, Palacios F, Durán D, Carballo J, Corrado R, de la Fuente J, López JA, and Vives C. 2021b Efficacy of a Multiresistant Vaginal Gel in treating HPV-Dependent Cervical lesions and HR-HPV Clearance. J Clin Pathol. 2020 Sep;73(9):1515. doi:10.1136/clin-2020-025019. 3. Sánchez L, Gómez J, Durán D, Fariña J, Soriano L, González S, López C, Martín E, and Vives C. Effect of a Multiresistant Vaginal Gel on High-Risk HPV-Infected Patients: Results of Different Studies. J Low Genit Tract Dis. 2020 April; 24(2):151-161. doi:10.1097/LGT.0000000000000028. 4. Sánchez L, Gómez J, Palacios F, et al. Tratamiento con vacuna de la lesión de la lesión cervical asociada al HPV en pacientes con lesión de la vagina en el diagnóstico. Anales de Medicina 2019; 47(1):1-10.